# CDKN2A

## Overview
The CDKN2A gene, located on chromosome 9p21, is a critical regulator of the cell cycle and plays a pivotal role in tumor suppression. It encodes the protein cyclin-dependent kinase inhibitor 2A (p16^INK4a), which inhibits cyclin-dependent kinases CDK4 and CDK6, thereby controlling the cell cycle's progression from the G1 phase to the S phase. This inhibition is crucial for maintaining the integrity of the cell cycle and preventing uncontrolled cellular proliferation, often associated with cancer development. The gene is also known for its involvement in cellular aging and senescence, further underscoring its importance in cell cycle regulation and cancer biology. Additionally, an alternative reading frame within CDKN2A produces another protein, p14^ARF, which contributes to tumor suppression through regulation of the p53 pathway, highlighting the gene's multifaceted role in cellular control and oncogenesis (Iolascon1998Analysis; Smith-SÃ¸rensen1996CDKN2A; BostrÃ¶m2001Alterations).

## Structure
The CDKN2A gene encodes the p16 INK4a protein, which is characterized by its ankyrin repeat structure. This structure includes multiple copies of a helix-loop-helix motif flanked by beta strands, linked by beta hairpins from adjacent repeats, forming an extended 'L' shape with a limited hydrophobic core (Ruas1999Functional). The protein consists of four ankyrin repeats, each contributing to the overall tertiary structure, essential for the formation of the ankyrin repeat fold and the tertiary interactions between neighboring repeat units (Kannengiesser2009Functional). 

The interaction of p16 INK4A with CDK6, as modeled in the crystal structure of a complex with CDK6, highlights the relevance of certain residues in close contact with CDK6, affecting the protein's function and interaction capabilities (Kannengiesser2009Functional). Specific mutations in p16 INK4a, such as those affecting core amino acids like L16, A20, and P48, can disrupt the mainchain hydrogen bonds and perturb helical packing, leading to a loss of function (Ruas1999Functional). Other mutations like A118T, located in the hydrophobic core, can accommodate changes without complete loss of function but still show impaired activity in functional assays (Ruas1999Functional).

The structure also includes critical residues at the INK4-CDK interface, such as D84, which forms a salt bridge essential for maintaining interaction with CDK6 (Ruas1999Functional). The convex face of the protein binds to CDK6, with the beta hairpins lying across the top of the CDK's N-terminal lobe and the base of the alpha helical region making contacts with the C-terminal lobe (Ruas1999Functional).

## Function
The CDKN2A gene encodes for the p16INK4a protein, which is a crucial regulator of the cell cycle, particularly at the G1 checkpoint. This protein functions by inhibiting cyclin-dependent kinases CDK4 and CDK6, which are essential for the phosphorylation of the retinoblastoma protein (pRb). The phosphorylation of pRb is necessary for the cell to progress from the G1 phase to the S phase. By inhibiting this process, p16INK4a induces a G1 arrest, effectively halting the cell cycle to prevent uncontrolled cell division (Cody1999Differential; Smith-SÃ¸rensen1996CDKN2A; BostrÃ¶m2001Alterations).

Additionally, CDKN2A is involved in cellular senescence and aging by blocking CDK4 and CDK6, thereby preventing abnormal cell proliferation and growth, acting as a major tumor suppressor (Mori2021Blood). The gene is located on chromosome 9p21, a region known for frequent alterations in various human cancers, highlighting its role in maintaining cellular integrity and preventing tumorigenesis (Iolascon1998Analysis).

The alternative reading frame of CDKN2A encodes another protein, p14 ARF, which plays a role in regulating the activity of the p53 tumor suppressor protein by interacting with Mdm2. This interaction prevents the degradation of p53, thus contributing to cell cycle control and apoptosis (BostrÃ¶m2001Alterations).

## Clinical Significance
CDKN2A mutations are significantly linked to increased risks of several cancers, most notably melanoma and pancreatic cancer. In familial melanoma, mutations in CDKN2A account for up to 40% of the increased susceptibility to this cancer, highlighting its critical role in tumor suppression and cell cycle regulation (McWilliams2010Prevalence). These mutations also show a high penetrance, with a notably increased cumulative risk of developing melanoma and pancreatic cancer by age 80 among carriers compared to non-carriers (McWilliams2010Prevalence). 

In pancreatic cancer, somatic mutations in CDKN2A are present in up to 95% of tumors, underscoring its pivotal role in the development of this malignancy (McWilliams2010Prevalence). Beyond these, CDKN2A mutations or alterations have also been associated with other cancers such as breast cancer, brain cancer, head and neck cancers, and non-melanoma skin cancers (McWilliams2010Prevalence).

In the context of acute lymphoblastic leukemia (ALL), CDKN2A/B deletions disrupt cell-cycle, apoptosis, and senescence-signaling pathways, leading to increased cell cycling, mutation accumulation, clonal heterogeneity, drug resistance, and tumor progression (GonzÃ¡lez-Gil2021The). These deletions are observed both at diagnosis and relapse, with a tendency for more frequent deletions at relapse, suggesting a role in disease progression and treatment resistance (GonzÃ¡lez-Gil2021The).

## Interactions
The CDKN2A gene encodes the p16^INK4a protein, which is known for its role in inhibiting cyclin-dependent kinases, specifically CDK4 and CDK6. This inhibition is crucial for regulating the cell cycle at the G1 checkpoint, preventing the phosphorylation of the retinoblastoma protein (pRB) and thus controlling cell proliferation. The p16 protein binds to CDK6, forming a complex that distorts the kinase's ATP-binding site and cyclin-binding site, rendering it inactive. This interaction involves the concave surface of p16's ankyrin repeats contacting the convex face of CDK6's N-lobe beta-sheet, with additional contacts at the C lobe's T loop and catalytic cleft (Russo1998Structural).

Furthermore, p16^INK4a interacts with CDK4 in a similar manner, blocking the formation of active kinase complexes with D-type cyclins, which is significant for cell cycle regulation. Specific mutations in CDKN2A can impair this interaction, affecting cell cycle control and contributing to unchecked cell growth and transformation, as seen in various cancers (Jones2007A; Torre2001CDKN2A).

Additionally, p16^INK4a can influence the efficacy of CDK4/6 inhibitor drugs like palbociclib by modulating the drug's target engagement, suggesting a potential role as a biomarker for predicting the sensitivity of cancer cells to these inhibitors (Green2019Direct).


## References


[1. (Jones2007A) Rebecca Jones, Margarida Ruas, Fiona Gregory, Stephanie Moulin, Domenico Delia, Siranoush Manoukian, Janice Rowe, Sharon Brookes, and Gordon Peters. A cdkn2a mutation in familial melanoma that abrogates binding of p16ink4a to cdk4 but not cdk6. Cancer Research, 67(19):9134â9141, October 2007. URL: http://dx.doi.org/10.1158/0008-5472.can-07-1528, doi:10.1158/0008-5472.can-07-1528. (60 citations) 10.1158/0008-5472.can-07-1528](https://doi.org/10.1158/0008-5472.can-07-1528)

[2. (GonzÃ¡lez-Gil2021The) Celia GonzÃ¡lez-Gil, Jordi Ribera, Josep Maria Ribera, and EulÃ lia GenescÃ . The yin and yang-like clinical implications of the cdkn2a/arf/cdkn2b gene cluster in acute lymphoblastic leukemia. Genes, 12(1):79, January 2021. URL: http://dx.doi.org/10.3390/genes12010079, doi:10.3390/genes12010079. (20 citations) 10.3390/genes12010079](https://doi.org/10.3390/genes12010079)

[3. (Smith-SÃ¸rensen1996CDKN2A) Birgitte Smith-SÃ¸rensen and Eivind Hovig. Cdkn2a (p16ink4a) somatic and germline mutations. Human Mutation, 7(4):294â303, 1996. URL: http://dx.doi.org/10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9, doi:10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9. (120 citations) 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9](https://doi.org/10.1002/(SICI)1098-1004(1996)7:4)

[4. (BostrÃ¶m2001Alterations) Jan BostrÃ¶m, Birgit Meyer-Puttlitz, Marietta Wolter, Britta Blaschke, Ruthild G. Weber, Peter Lichter, Koichi Ichimura, V. Peter Collins, and Guido Reifenberger. Alterations of the tumor suppressor genes cdkn2a (p16), p14, cdkn2b (p15), and cdkn2c (p18) in atypical and anaplastic meningiomas. The American Journal of Pathology, 159(2):661â669, August 2001. URL: http://dx.doi.org/10.1016/s0002-9440(10)61737-3, doi:10.1016/s0002-9440(10)61737-3. (349 citations) 10.1016/s0002-9440(10)61737-3](https://doi.org/10.1016/s0002-9440(10)61737-3)

[5. (Green2019Direct) Jennifer L. Green, Eric S. Okerberg, Josilyn Sejd, Marta Palafox, Laia Monserrat, Senait Alemayehu, Jiangyue Wu, Maria Sykes, Arwin Aban, Violeta Serra, and Tyzoon Nomanbhoy. Direct cdkn2 modulation of cdk4 alters target engagement of cdk4 inhibitor drugs. Molecular Cancer Therapeutics, 18(4):771â779, April 2019. URL: http://dx.doi.org/10.1158/1535-7163.mct-18-0755, doi:10.1158/1535-7163.mct-18-0755. (39 citations) 10.1158/1535-7163.mct-18-0755](https://doi.org/10.1158/1535-7163.mct-18-0755)

[6. (Torre2001CDKN2A) G Della Torre, B Pasini, S Frigerio, R Donghi, D Rovini, D Delia, G Peters, T J G Huot, G Bianchi-Scarra, F Lantieri, M Rodolfo, G Parmiani, and M A Pierotti. Cdkn2a and cdk4 mutation analysis in italian melanoma-prone families: functional characterization of a novel cdkn2a germ line mutation. British Journal of Cancer, 85(6):836â844, September 2001. URL: http://dx.doi.org/10.1054/bjoc.2001.1991, doi:10.1054/bjoc.2001.1991. (85 citations) 10.1054/bjoc.2001.1991](https://doi.org/10.1054/bjoc.2001.1991)

[7. (Mori2021Blood) Hiroaki Mori, Yu Funahashi, Yuta Yoshino, Hiroshi Kumon, Yuki Ozaki, Kiyohiro Yamazaki, Shinichiro Ochi, Ayumi Tachibana, Taku Yoshida, Hideaki Shimizu, Takaaki Mori, Jun-ichi Iga, and Shu-ichi Ueno. Blood cdkn2a gene expression in aging and neurodegenerative diseases. Journal of Alzheimerâs Disease, 82(4):1737â1744, August 2021. URL: http://dx.doi.org/10.3233/jad-210483, doi:10.3233/jad-210483. (10 citations) 10.3233/jad-210483](https://doi.org/10.3233/jad-210483)

[8. (Kannengiesser2009Functional) Caroline Kannengiesser, Sharon Brookes, Anna Gutierrez del Arroyo, Danielle Pham, Johny Bombled, Michel Barrois, Olivier Mauffret, Marie-Franï¿½ï¿½oise Avril M, Agnï¿½ï¿½s Chompret, Gilbert M. Lenoir, Alain Sarasin, Gordon Peters, and Brigitte Bressac-de Paillerets. Functional, structural, and genetic evaluation of 20cdkn2agerm line mutations identified in melanoma-prone families or patients. Human Mutation, 30(4):564â574, April 2009. URL: http://dx.doi.org/10.1002/humu.20845, doi:10.1002/humu.20845. (47 citations) 10.1002/humu.20845](https://doi.org/10.1002/humu.20845)

[9. (Cody1999Differential) D.T. Cody, Yuanhui Huang, C.J. Darby, G.K. Johnson, and F.E. Domann. Differential dna methylation of the p16 ink4a/cdkn2a promoter in human oral cancer cells and normal human oral keratinocytes. Oral Oncology, 35(5):516â522, September 1999. URL: http://dx.doi.org/10.1016/s1368-8375(99)00026-3, doi:10.1016/s1368-8375(99)00026-3. (47 citations) 10.1016/s1368-8375(99)00026-3](https://doi.org/10.1016/s1368-8375(99)00026-3)

[10. (Ruas1999Functional) Margarida Ruas, Sharon Brookes, Neil Q McDonald, and Gordon Peters. Functional evaluation of tumour-specific variants of p16ink4a/cdkn2a: correlation with protein structure information. Oncogene, 18(39):5423â5434, September 1999. URL: http://dx.doi.org/10.1038/sj.onc.1202918, doi:10.1038/sj.onc.1202918. (97 citations) 10.1038/sj.onc.1202918](https://doi.org/10.1038/sj.onc.1202918)

[11. (Russo1998Structural) Alicia A. Russo, Lily Tong, Jie-Oh Lee, Philip D. Jeffrey, and Nikola P. Pavletich. Structural basis for inhibition of the cyclin-dependent kinase cdk6 by the tumour suppressor p16ink4a. Nature, 395(6699):237â243, September 1998. URL: http://dx.doi.org/10.1038/26155, doi:10.1038/26155. (391 citations) 10.1038/26155](https://doi.org/10.1038/26155)

[12. (McWilliams2010Prevalence) Robert R McWilliams, Eric D Wieben, Kari G Rabe, Katrina S Pedersen, Yanhong Wu, Hugues Sicotte, and Gloria M Petersen. Prevalence of cdkn2a mutations in pancreatic cancer patients: implications for genetic counseling. European Journal of Human Genetics, 19(4):472â478, December 2010. URL: http://dx.doi.org/10.1038/ejhg.2010.198, doi:10.1038/ejhg.2010.198. (166 citations) 10.1038/ejhg.2010.198](https://doi.org/10.1038/ejhg.2010.198)

[13. (Iolascon1998Analysis) Achille Iolascon, Lucia Giordani, Arcangela Moretti, Giuseppe Basso, Adriana Borriello, and Fulvio Della Ragione. Analysis of cdkn2a, cdkn2b, cdkn2c, and cyclin ds gene status in hepatoblastoma. Hepatology, 27(4):989â995, April 1998. URL: http://dx.doi.org/10.1002/hep.510270414, doi:10.1002/hep.510270414. (48 citations) 10.1002/hep.510270414](https://doi.org/10.1002/hep.510270414)